Abstract: A system for cooling a two-dimensional array of computing devices is disclosed. A fan is configured to move air through the array of computing devices, which may be fan-less. The fan's width and height may correspond to the two-dimensional array's width and height. The two-dimensional array may be radially configured, and a shroud may be connected between the fan and the array of computing devices. The shroud may have profiles matching the fan and the array of computing devices.

Abstract: An analyte sensor is disclosed. The analyte sensor includes an implantable sensor configured to measure a signal indicative of an analyte concentration in a user and at least one membrane layer. The membrane layer is disposed over at least a portion of the sensor. The membrane includes a membrane polymer matrix including an ethylene vinyl acetate copolymer and a therapeutic agent dispersed within the membrane polymer matrix. The membrane layer is permeable to an analyte. Devices and methods for monitoring analytes are also disclosed.

Abstract: One example includes a method for measuring a quiescent current in a switching voltage regulator. The method includes generating a mathematical model of a circuit design associated with the switching voltage regulator. The mathematical model includes measurable parameters to describe a switching current of a power switch of the switching voltage regulator. The method also includes fabricating a circuit comprising the switching voltage regulator based on the circuit design. The fabricated circuit includes the power switch and conductive I/O. The method also includes coupling the conductive I/O of the fabricated circuit to a circuit test fixture and providing electrical signals to the conductive I/O via the circuit test fixture. The method also includes measuring the measurable parameters in response to the electrical signals and applying the measurable parameters to the mathematical model to calculate the switching current.

Abstract: Disclosed herein are evaporator assemblies for heat pump systems. The evaporator units can comprise a housing defining an interior chamber, an air inlet and an air outlet. The air inlet and the air outlet can form an air flow path through the interior chamber, and an evaporator unit can be positioned within the interior chamber such that the air flow path contacts the evaporator unit. The air inlet having a semi-circular cross section through which air flows into the interior chamber, the semi-circular cross section having a straight edge and a curved edge. A velocity magnitude of the air flowing from the air inlet into contact with the evaporator unit can deviate less than 0.1 m/s from the average air velocity across the surface area of the evaporator.

Abstract: The disclosures herein generally relate to a vehicle and more particularly, to an all-terrain utility vehicle which can perform multiple operations, in varied terrain and soil conditions, with precision and guidance. An all-terrain utility vehicle mainly includes wheel track and wheel base adjusting system, a height adjusting system, a plurality of vertical axle assemblies, a steering system, an implement position adjusting system, a master controller unit and a plurality of wheel drive motors. All the vehicle functions being controlled and guided with the help of an electronic master control module which enables optional manual, remote and autonomous operations. The electronic master control module utilizes externally acquired location data and digital maps with soil and plant information for enabling precision field operations.

Abstract: The present invention relates in general to compositions and methods for treating an animal or human patient in need of treatment for ophthalmic diseases or conditions involving oxidative stress and treatment with an ophthalmic implant containing (2R,2R?)-3,3?-disulfanediyl bis(2-cetamidopropanamide) (diNACA), wherein such ophthalmic diseases or conditions include but not limited to cataracts, cataracts in a subject that does not have diabetes, corneal endothelial cell loss, age-related macular degeneration, presbyopia, retinitis pigmentosa (RP), Usher syndrome, Stargardt syndrome, glaucoma, diabetic retinopathy, and/or retinal disease.

Abstract: One example includes a method for measuring a quiescent current in a switching voltage regulator. The method includes generating a mathematical model of a circuit design associated with the switching voltage regulator. The mathematical model includes measurable parameters to describe a switching current of a power switch of the switching voltage regulator. The method also includes fabricating a circuit comprising the switching voltage regulator based on the circuit design. The fabricated circuit includes the power switch and conductive I/O. The method also includes coupling the conductive I/O of the fabricated circuit to a circuit test fixture and providing electrical signals to the conductive I/O via the circuit test fixture. The method also includes measuring the measurable parameters in response to the electrical signals and applying the measurable parameters to the mathematical model to calculate the switching current.

Abstract: A monolithic implantable device for delivery of an antibody is provided. The implantable device comprises a polymer matrix within which is dispersed a pharmaceutical formulation that includes one or more therapeutic agents and optionally, one or more excipients. The therapeutic agents contain an antibody and the polymer matrix contains a hydrophobic polymer. Within a time period of 35 days, the device exhibits a cumulative weight-based release ratio of the antibody of from about 20% to about 60%.

Abstract: Disclosed herein are evaporator assemblies for heat pump systems. The evaporator units can comprise a housing defining an interior chamber, an air inlet and an air outlet. The air inlet and the air outlet can form an air flow path through the interior chamber, and an evaporator unit can be positioned within the interior chamber such that the air flow path contacts the evaporator unit. The air inlet having a semi-circular cross section through which air flows into the interior chamber, the semi-circular cross section having a straight edge and a curved edge. A velocity magnitude of the air flowing from the air inlet into contact with the evaporator unit can deviate less than 0.1 m/s from the average air velocity across the surface area of the evaporator.

Abstract: Systems and methods for managing airflow for cooling computing devices in a data center in normal and cold environments are disclosed. Computing devices are positioned on racks, and an air barrier may be connected to the racks and have openings configured to permit air to be drawn through the computing devices by cooling fans. In a first mode, cool air may be drawn in from a cold aisle, and heated air may be exhausted into a hot aisle. Temperature sensors may periodically measure temperatures for the cool air being drawn into the computing devices. A controller may select a subset of the computing devices for air flow reversal in response to the measured temperatures being below a predetermined threshold. Patterns that may be time-varying and temperature-varying may be used to select the computing devices for air flow reversal and to adjust the fan speed of the computing devices.

Abstract: The present invention comprises a polymer and/or polymer composite based sleeve to be fitted between an extended body, such the neck, trunnion, and/or stem of a hip implant, and a receiving body, such as a femoral head in a hip implant, that reduces wear, decreases toxic material from wear debris, enhances the mechanical connection of the extension and receiving body, reduces or eliminates impingement with receiving body, delocalize stress concentrations, and may also serve as a modifying junction between an extension and receiving body of unmatched size. The polymeric based sleeve presently disclosed comprises an inert and/or biologically favorable material which may be used in its virgin form or contain biocompatible additives. In order to best match patient and implant requirements, modifications may be made in the length, thickness, composition, as well as the presence of a taper, or lack thereof, in order to be compatible with existing devices.

Abstract: An implantable device for delivery of a tyrosine kinase inhibitor is provided. The device comprises a core defining an outer peripheral surface. The core comprises a core polymer matrix within which is dispersed a tyrosine kinase inhibitor. The polymer matrix contains an ethylene vinyl acetate copolymer.

Abstract: A method for prohibiting and/or treating an eye condition is provided. The method comprises inserting an implantable device into a suprachoroidal space of a patient. The device comprises a core defining an outer peripheral surface. The core comprises a core polymer matrix within which is dispersed a therapeutic agent, the polymer matrix containing an ethylene vinyl acetate copolymer.

Abstract: An implantable device for prohibiting and/or treating an inflammatory eye condition is provided. The device comprises a core defining an outer peripheral surface. The core comprises a core polymer matrix within which is dispersed at least a steroidal agent, the polymer matrix containing an ethylene vinyl acetate copolymer.

Abstract: One example includes a testing method that includes connecting a capacitor having a first capacitance to an output terminal of an integrated circuit (IC). The method can also include generating pulse signal responsive to an enable signal provided at at least one input terminal of the IC and providing a drive signal to the output terminal to cause a linearly increasing voltage across the capacitor responsive to the pulse signal. The method can also include measuring a no-load delay. The method can also include measuring the linearly increasing voltage at the output terminal responsive to the drive signal. The method can also include determining a first capacitance charge time for the capacitor responsive to the linearly increasing voltage reaching a threshold and determining a second capacitance charge delay for a second capacitance based on the first capacitance charge time and the no-load delay.

Abstract: An implantable medical device is provided. The device comprises a drug release layer, wherein the drug release layer comprises a naked nucleic acid dispersed within a polymer matrix. The polymer matrix includes an ethylene vinyl acetate copolymer and has a melting temperature of from about 20° C. to about 100° C. as determined in accordance with ASTM D3418-15 and a melt flow index of from about 0.2 to about 100 gram per 10 minutes as determined in accordance with ASTM D1238-20 at a temperature of 190° C. and a load of 2.16 kilograms.

Abstract: An implantable device for delivery of a macromolecular drug compound is provided. The device comprises a core having an outer surface and a membrane layer positioned adjacent to the outer surface of the core. The core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 0.5 kDa or more, the polymer matrix containing a hydrophobic polymer. Further, the membrane layer comprises a plurality of water-soluble particles distributed within a membrane polymer matrix containing an ethylene vinyl acetate copolymer, wherein the water-soluble particles have a D50 particle size of about 150 micrometers or less and contain a non-polymeric, hydroxy-functional compound.

Abstract: The present invention relates to an improved process of preparation of Ivosidenib a compound of Formula (I). More particularly, present invention provides process of preparation of intermediates. Also provide process of preparation of amorphous form of Ivosidenib. Further, present invention provides process of preparation of chirally pure Ivosidenib a compound of Formula (I).

Abstract: An implantable medical device is provided. The device comprises a drug release layer, wherein the drug release layer contains particles dispersed within a polymer matrix. The lipid particles include a carrier component that contains a carrier (e.g., peptide, protein, carbohydrate, lipid, polymer, etc.) and encapsulates a nucleic acid, wherein the polymer matrix includes an ethylene vinyl acetate copolymer. The ratio of the melting temperature of the ethylene vinyl acetate copolymer to the melting temperature of the carrier is about 2° C./° C. or less.

Abstract: An implantable medical device is provided. The device comprises a drug release layer, wherein the drug release layer comprises a naked nucleic acid dispersed within a polymer matrix. The polymer matrix includes an ethylene vinyl acetate copolymer and has a melting temperature of from about 20° C. to about 100° C. as determined in accordance with ASTM D3418-15 and a melt flow index of from about 0.2 to about 100 gram per 10 minutes as determined in accordance with ASTM D1238-20 at a temperature of 190° C. and a load of 2.16 kilograms.